Furthermore, CAR-NK92 cells targeting CD133, when used with cisplatin, exhibit significant anti-tumor effects in ovarian cancer, with cisplatin not affecting the cytotoxicity or viability of CAR-NK cells (68). This evidence concerns the gene PROM1 and ovarian carcinoma.